Furthermore, the limited number of NSCLC patients with weak or no Trop-2 staining precludes predicting the efficacy of this treatment and its correlation with clinicopathological characteristics based on Trop-2 expression levels. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.